跳至主要内容
临床试验/NCT05103995
NCT05103995已完成不适用

Impact of Donor-recipient ABO Matching on Patients' Outcome After Peripheral Blood Stem Cell Haploidentical Stem Cell Transplantation

First Affiliated Hospital of Zhejiang University2 个研究点 分布在 1 个国家目标入组 510 人开始时间: 2013年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
510
试验地点
2
主要终点
5-year Overall Survival

研究概览

简要总结

the impact of donor-recipient ABO matching on outcome of peripheral blood stem cell haploidentical hematopoietic stem cell transplantation

详细描述

The impact of donor-recipient ABO compatibility on transplant outcomes had been evaluated in different transplant settings, but had shown different results. The investigators set out to investigate the impact of ABO incompatibility on post-transplant outcomes, engraftment kinetics and blood product requirements, transfusion independence, the incidence of poor graft function (PGF) in anti-T-lymphocyte globulin (ATG) based haplo-SCT with PBSC grafts.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
15 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The subjects or their legal representatives signed the informed consent before the clinical study.
  • Subjects aged 15-70 years.
  • Patients with malignant hematological diseases plan to receive allogeneic peripheral blood stem cell transplantation
  • Patients have no suitable HLA identical sibling donor 5.Patients with malignant hematological diseases plan to receive HLA haploidentical stem cell transplantation
  • Subjects with ECoG score of 0-2.

排除标准

  • 1.Patients have suitable HLA identical sibling donor
  • Patients with severe liver and kidney function (alanine aminotransferase > 2.5 times of the upper normal limit, serum creatinine > 1.5 times of the upper normal limit), cardiopulmonary dysfunction (cardiac function NYHA III / IV, cardiac ejection fraction < 50%, severe obstructive or restrictive ventilation dysfunction);
  • Patients with active infection;
  • patients diagnosed with aplastic anemia before transplantation or died within 2 months after transplantation;
  • Subjects with ECoG score > 2;
  • Patients with secondary tumor;
  • Patients who cannot independently choose to enter or exit clinical trials due to serious central nervous system disease or mental disease.

结局指标

主要结局

5-year Overall Survival

时间窗: 5 year

5-year Overall Survival

次要结局

  • the 5-year cumulative incidence of graft failure(5-year)
  • 5-year cumulative incidence of chronic graft versus host disease(5 year)
  • 365-day blood transfusion requirements(365 day)
  • cumulative incidence of blood transfusion independence within 60 days after transplantation(60 day)
  • 5-year Non-relapse mortality(5 year)
  • 28-day cumulative incidence of neutrophils engraftment(28 day)
  • 28-day cumulative incidence of platelets engraftment(28 day)
  • the 5-year cumulative incidence of poor graft function the incidence of poor graft function(5 year)
  • 100-day cumulative incidence of acute graft versus host disease(100-day)

研究者

发起方
First Affiliated Hospital of Zhejiang University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yi Luo

Principal Investigator

First Affiliated Hospital of Zhejiang University

研究点 (2)

Loading locations...

相似试验